跳至主要内容
临床试验/NCT00886067
NCT00886067已完成1 期

An Open-label Positron Emission Tomography (PET) Study Using 2 [18F] F A85380 to Determine α4β2 Neuronal Nicotinic Receptor (NNR) Occupancy of AZD1446 After Oral Administration to Male and Non-fertile Female (Non-nicotine Users) Healthy Volunteers

AstraZeneca1 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2009年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
AstraZeneca
入组人数
11
试验地点
1
主要终点
Determine whether and to what extent AZD1446 can displace radioligand 2-[18F]-F-A85380 from binding to α4β2 neuronal nicotinic receptors (NNRs) and to describe the relationship between plasma concentrations of AZD1446 and its occupancy at α4β2 NNRs.

研究概览

简要总结

The primary purpose is to study the occupancy at the α4β2 neuronal nicotinic receptor's (NNRs) and to determine the relation between plasma concentration of AZD1446 and the occupancy at α4β2 NNRs.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
20 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Physically healthy volunteers
  • Body weight between 50 to 100 kg and body mass index (BMI) between 19 and 30 kg/m2

排除标准

  • History of any clinically significant disease or disorder
  • History of severe allergy/hypersensitivity reactions
  • Participation in a PET examination as part of a scientific study during the past twelve months

研究组 & 干预措施

2-[18F]-F-A85380

Experimental

Single microdose

干预措施: 2-[18F]-F-A85380 (Radiation)

AZD1446

Experimental

Single oral administration

干预措施: AZD1446 (Drug)

结局指标

主要结局

Determine whether and to what extent AZD1446 can displace radioligand 2-[18F]-F-A85380 from binding to α4β2 neuronal nicotinic receptors (NNRs) and to describe the relationship between plasma concentrations of AZD1446 and its occupancy at α4β2 NNRs.

时间窗: One PET assessment on baseline day and one PET assessment at the drug treatment day

Plasma concentration (Cmax, tmax, AUC)

时间窗: During time period of the PET assessment

次要结局

  • Safety and tolerability (AEs, vital signs, lab)(During the whole study)

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验